Active Secondary Progressive Multiple Sclerosis
2 clinical trials · Condition
◉ Watch Active Secondary Progressive Multiple Sclerosis
| Record | Firm | Date |
|---|---|---|
| Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy (NCT05376579) | Novartis Pharmaceuticals | 2022-06-17 |
| Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (NCT04940065) | Novartis Pharmaceuticals | 2021-06-30 |
Track Active Secondary Progressive Multiple Sclerosis automatically
Every clearance here is in the API, with alerts when new ones post.